Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Sweis on Sequencing of Therapies in Prostate Cancer

October 12th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the sequencing of therapies in prostate cancer.

Dr. Daskivich Discusses Active Surveillance in Prostate Cancer

October 10th 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses active surveillance for patients with prostate cancer.

Dr. Sharma Discusses Immunotherapy in Prostate Cancer

October 5th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immunotherapy in prostate cancer.

Prostate Cancer Paradigm Progresses, But Unanswered Questions Remain

October 4th 2018

Randy F. Sweis, MD, discusses recent progress and next steps in the prostate cancer paradigm.

Dr. Steinberg on the Management of Prostate Cancer

October 2nd 2018

Gary D. Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the management of patients with prostate cancer.

FDA Grants Rucaparib Breakthrough Designation for mCRPC

October 2nd 2018

The FDA has granted the PARP inhibitor rucaparib a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer following at least 1 androgen receptor–directed therapy and taxane-based chemotherapy.

Challenges Remain in Prostate Cancer Paradigm

September 25th 2018

Walter M. Stadler, MD, gives an overview of the current prostate cancer landscape and discussed future directions.

Dr. Stadler on Sequencing Therapies in Prostate Cancer

September 22nd 2018

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.

Patient-Centered Focus Drives Growth at Virginia Urology

September 19th 2018

Virginia Urology, a practice with specialists in surgery, radiation, and oncology, has grown steadily over 75 years by remaining patient focused. Centered in Richmond, Virginia Urology has always prioritized quality care.

Dr. Daskivich on the Future Landscape of Prostate Cancer

September 19th 2018

Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.

Personalized Medicine in Prostate Cancer: Now More Precise

September 18th 2018

Raoul S. Concepcion, MD, FACS, discusses the explosion of molecular testing in the urology world.

Apalutamide Maintains Health-Related QoL in Nonmetastatic CRPC

September 17th 2018

Fred Saad, MD, discusses the clinical significance of the SPARTAN trial, the HRQoL data, and remaining steps in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. George on Rationale for Abi Race Prostate Cancer Study

September 14th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the rationale for the Abi Race study looking at men with metastatic castration-resistant prostate cancer.

Dr. Posadas on Unmet Needs in Prostate Cancer

September 13th 2018

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses unmet needs in prostate cancer.

Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an Option

September 11th 2018

Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.

NCI Expert Stresses Importance of Multimodal Imaging in Prostate Cancer

September 7th 2018

Peter L. Choyke, MD, FACP, discusses the clinical implications of emerging technologies for prostate cancer imaging.

Dr. Hussain on Interest in Using PARP Inhibitors in Prostate Cancer

September 6th 2018

Maha Hussain, MD, FACP, FASCO, Genevieve Teuton Professor of Medicine, Deputy Director, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses the interest in using PARP inhibitors in patients with prostate cancer.

Enzalutamide/Radium-223 Combo Shows Tolerability in mCRPC

September 5th 2018

Benjamin L. Maughan, MD, PharmD, discusses the tolerability of combining radium-223 dichloride and enzalutamide, as well as the next steps with this combination.

Dr. George on Results of the Abi Race Study for Prostate Cancer

August 27th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses results of the Abi Race study for patients with metastatic castration-resistant prostate cancer.

Experts Delve Into 4 Phenotypes of Advanced Prostate Cancer

August 20th 2018

A panel of experts during an OncLive PeerExchange® provided practical definitions for biochemical recurrent hormone-naïve nonmetastatic, metastatic hormone-naïve advancing, nonmetastatic castration-resistant, and metastatic castration-resistant prostate cancer.